Přístupnostní navigace
E-application
Search Search Close
Publication detail
FOJTŮ, M. GUMULEC, J. STRAČINA, T. RAUDENSKÁ, M. SKOTÁKOVÁ, A. VACULOVIČOVÁ, M. ADAM, V. BABULA, P. NOVÁKOVÁ, M. MASAŘÍK, M.
Original Title
Reduction of doxorubicin-induced cardiotoxicity using nanocarriers: A review
Type
journal article in Web of Science
Language
English
Original Abstract
Background: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet.
Keywords
Doxorubicin; nanoparticles; liposomal; polymeric; protein; gold; cardiotoxicity; nanocarriers
Authors
FOJTŮ, M.; GUMULEC, J.; STRAČINA, T.; RAUDENSKÁ, M.; SKOTÁKOVÁ, A.; VACULOVIČOVÁ, M.; ADAM, V.; BABULA, P.; NOVÁKOVÁ, M.; MASAŘÍK, M.
Released
11. 7. 2017
ISBN
1389-2002
Periodical
CURRENT DRUG METABOLISM
Year of study
18
Number
3
State
United Arab Emirates
Pages from
237
Pages to
263
Pages count
27
BibTex
@article{BUT137709, author="Michaela {Fojtů} and Jaromír {Gumulec} and Tibor {Stračina} and Martina {Raudenská} and Anna {Skotáková} and Markéta {Vaculovičová} and Vojtěch {Adam} and Petr {Babula} and Marie {Nováková} and Michal {Masařík}", title="Reduction of doxorubicin-induced cardiotoxicity using nanocarriers: A review", journal="CURRENT DRUG METABOLISM", year="2017", volume="18", number="3", pages="237--263", doi="10.2174/1389200218666170105165444", issn="1389-2002" }